Find Academic Supervisors

• Stroke
• Neuroplasticity
• Brain Ischemia
• +9 more

Jialing Liu is a Professor at the University of California, San Francisco (UCSF) in the Department of Neurological Surgery and affiliated with the UCSF Weill Institute for Neurosciences. Their academic journey includes a PhD in Immunology from Boston University Medical Center and postdoctoral studies at UCSF's Graduate Division. Research Interests: Dr. Liu's work focuses on post-stroke neuroplasticity, vascular remodeling, and the impact of comorbidities like type 2 diabetes on neurological outcomes. Key areas include brain oscillations, neurovascular unit dynamics, and therapeutic interventions such as environmental enrichment and pharmacological neuroprotection. Recent Article Trends: Recent publications emphasize stroke-induced alterations in brain connectivity, diabetic effects on hippocampal oscillations, and vascular biomarkers for cognitive decline. Collaborative studies span neuroimaging, immunomodulation, and translational models. Scientific Awards: BLR&D Research Career Scientist Award (NIH IK6BX004600) Grants and Collaborations: Dr. Liu has led multiple NIH-funded projects since 2001, including R01, R21, and I01 grants. Their research involves collaborations with co-authors like Midori Yenari, Philip Weinstein, and Frank Sharp, utilizing advanced techniques like closed-loop electrophysiological systems and transcriptomic profiling. Labs and Teams: Affiliated with the UCSF Department of Neurological Surgery and the Weill Institute for Neurosciences, Dr. Liu's team integrates stroke models, neuroimaging, and molecular biology to explore recovery mechanisms.

• Autoimmunity and Inflammation
• Immunology
• Cancer Research
• +4 more

Mikael Karlsson is a Professor at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. His research focuses on the regulation of the immune system, particularly B cells and macrophages, in autoimmune diseases and cancer. He leads the 'Inflammatory responses in cancer and autoimmunity' research group, which investigates mechanisms underlying autoimmunity, allergy, cardiovascular disease, and tumor microenvironments. Education: Docent (2009), Karolinska Institutet. Active collaborations include institutions such as the University of Toronto, Rockefeller University, and NIH. His group employs advanced techniques like multiphoton microscopy and flow cytometry. Research Interests: Autoimmunity (e.g., systemic lupus erythematosus), cancer immunology, B cell and macrophage interactions, and immunotherapy development. Key projects include targeting TAM macrophages in tumors and studying B cell dysregulation in autoimmune conditions. Publications: Over 100 articles in journals like Cancer Cell , Nature Communications , and Immunity , highlighting work on immune tolerance mechanisms, extracellular vesicle therapies, and cytokine signaling. Lab & Collaborations: Hosts PhD students and collaborates globally. Focus areas include developing novel treatments for autoimmune diseases and cancer through immune modulation.

• Neuroimmunology
• Stroke Recovery
• Brain Injury Mechanisms
• +3 more

Sunghee Cho, Ph.D., is a Professor of Neuroscience at Weill Cornell Medicine and serves as Lab Director at the Stroke Neuroimmunology Laboratory at Burke Neurological Institute. She is also affiliated with the Brain and Mind Research Institute and holds editorial roles at prominent journals including Stroke and Cerebral Blood Flow/Metabolism. Ph.D. in Neuroscience, Weill Cornell Medical College M.S. in Human Nutrition, Cornell University B.S. in Chemistry, Yonsei University Her research focuses on neuron-immune interactions in stroke-induced brain injury and repair mechanisms. Key areas include CD36 receptor signaling, blood-brain barrier dysfunction, monocyte infiltration, and metabolic modulation of stroke outcomes. Current studies investigate obesity's impact on stroke recovery and therapeutic targeting of neuroinflammatory pathways. Recent publications highlight trends in CD36 inhibition for neuroprotection, remote ischemic conditioning, and molecular mechanisms linking metabolic disorders with stroke severity. Collaborative work with the Ratan Lab explores ER stress pathways in neurodegeneration. Fellow of American Heart/Stroke Association (FAHA) NIH Neural Oxidative Metabolism and Death (NOMD) Study Section member Editorial roles at Stroke journals Her research is funded by NINDS, NHLBI, American Heart Association, Sanofi, and the Burke Foundation. She leads the Preclinical Stroke Modeling program at Burke Neurological Institute and collaborates with European research consortia.

• Endoplasmic Reticulum Stress
• Lipid Accumulation
• High-Fat Diet
• +4 more

Prof. Dr. Nesrin KARTAL ÖZER is a distinguished academic in Medical Biochemistry at Üsküdar University Faculty of Medicine (English). With a career spanning over four decades, she has held academic positions at Hacettepe University and Marmara University, achieving her Professor title in 1994. Her research focuses on endoplasmic reticulum stress, lipid accumulation, and metabolic diseases, particularly in the context of vitamin E's regulatory roles. Licence: Hacettepe University, Faculty of Pharmacy (1977) Doctorate: Hacettepe University, Faculty of Medicine (1983) Her work integrates biochemical mechanisms with clinical applications, emphasizing cholesterol-induced pathologies and antioxidant interventions. Recent publications highlight her contributions to understanding Nrf2 activation, lipid droplet dynamics, and inflammation resolution in metabolic diseases. As director of the Metabolic and Inflammatory Diseases Application and Research Center, she leads cutting-edge studies in metabolic stress pathways. Prof. Özer has actively participated in academic editing for journals like Free Radical Biology and Medicine and Mechanisms of Ageing and Development . She supervises numerous research projects and has contributed to international conferences on metabolic diseases and vitamin E biology. Her scientific network spans multiple disciplines including hepatology, cardiovascular research, and cancer biology.

Katie WraithView profile

Lecturer

• Cardiovascular Biology
• Platelet Function
• Coagulation Pathway
• +3 more

Katie Wraith is a Lecturer in Cardiovascular Biology at the Hull York Medical School (University of Hull). She leads a laboratory investigating platelet and coagulation pathway dysregulation in cardiovascular diseases, with a focus on oxidized low-density lipoproteins (oxLDL). Education: PhD in Medical Sciences (2013, Hull York Medical School) Career: Post-Doctoral Research Assistant (2013-2017, Naseem Lab); Senior Laboratory Research Scientist (2022-2024, Palmer Lab); Lecturer since 2024 Research Interests: Her work explores how oxLDL amplifies platelet activation and pro-coagulant responses in diseases like atherosclerosis. Key areas include thrombosis mechanisms, lipid metabolism, and signal transduction pathways. Recent Article Trends: Analysis of her publications (2013-2025) reveals consistent focus on oxLDL interactions with platelet receptors (CD36, αIIbβ3), hypoxia effects on platelet function, and dyslipidemia-induced hyperactivity mechanisms. Subfields include antiplatelet therapies, thrombin signaling, and fibrinogen modulation. Teaching: Delivers the Haemostasis and Thrombosis in Cardiovascular Diseases module for MB BS Medicine. Leads independent research projects across Biomedical Science and Health & Climate Change programs. Projects: Principal investigator for the MRC-funded RISE project (2024-2029) establishing super-resolution imaging for multimorbidity research.

Nikhlesh K. SinghView profile

Associate Professor

• Vascular Biology
• Ophthalmology
• Cardiovascular Disease
• +3 more

Nikhlesh K. Singh serves as Associate Professor at Wayne State University with dual appointments in the Integrative Biosciences Center (IBio) and the Department of Ophthalmology, Visual and Anatomical Sciences. His laboratory investigates molecular mechanisms driving vision-threatening retinal diseases and cardiovascular pathologies through innovative approaches in vascular biology and inflammation research. Dr. Singh's research program centers on two critical disease pathways: pathological retinal angiogenesis in diabetic retinopathy and age-related macular degeneration, and restenosis/atherosclerosis following vascular interventions. His team elucidates how inflammatory mediators like IL-33 and caspases regulate aberrant blood vessel formation in the retina, while simultaneously exploring cytoskeletal signaling in vascular smooth muscle cell migration during intimal hyperplasia. This dual focus bridges ophthalmology and cardiology through shared molecular mechanisms of vascular dysfunction. Analysis of his 15 most recent publications reveals consistent emphasis on inflammatory signaling pathways (IL-33, NOTCH, PKC), angiogenesis regulation, and emerging applications of nanotechnology. His work demonstrates particular strength in molecular characterization of disease mechanisms, with significant contributions to understanding retinal neovascularization and atherosclerotic plaque formation through rigorous biochemical and cellular approaches. Dr. Singh's laboratory has received notable recognition: Research photograph featured on front page of 7th Annual Vision Research Compendium (2020) Winners of 8th Annual Vision Research Day Research photograph featured on front page of 9th Annual Vision Research Compendium (2022) His research program is currently supported by NIH/NEI R01EY029709 funding, mentoring a diverse team including graduate student Anamika Sharma and postdoctoral fellows Geetika, Purnima Gogoi, and Shivantika Bisen. Former trainees include Dr. Deepti Sharma (Johns Hopkins University) and Dr. Shailendra Kumar Verma (La Jolla Institute of Immunology), reflecting his commitment to developing next-generation scientists. Based at the Integrative Biosciences Center (IBio) in Detroit, Dr. Singh leads a collaborative laboratory environment where molecular discovery drives translational applications for blinding retinal diseases and cardiovascular conditions, maintaining strong publication output in high-impact journals across ophthalmology, vascular biology, and molecular medicine.

Kenneth J LintonView profile

Professor

• Membrane Transport Biology
• ABC Transporters
• Cholestatic Liver Disease
• +4 more

Professor Kenneth J Linton serves as Professor of Protein Biochemistry, Director of Graduate Studies, and Molecular and Cellular Medicine Theme Lead at Queen Mary University of London's Blizard Institute within the Faculty of Medicine and Dentistry. His research focuses on membrane transport proteins and their pathophysiological roles in human disease, with particular expertise in ATP-binding cassette (ABC) transporters. His academic foundation includes a BSc in Biological Sciences with honours in Microbiology from the University of Edinburgh and a PhD in Genetics from the University of Glasgow. His doctoral work first described the molecular mechanism of antibiotic self-protection via ABC transporters in soil bacteria. Linton's research program investigates structure-function relationships in membrane transport proteins through: Molecular mechanisms of multidrug resistance P-glycoprotein (ABCB1) ABCB4/ABCB11 mutations in cholestatic liver disease CD36's role in atherosclerosis and obesity Fatty acid transport protein function in lipid metabolism Protein:protein interactions at plasma membranes His work integrates structural biology, molecular modeling, and cell biological approaches to elucidate disease mechanisms. Analysis of his 2018-2024 publications reveals sustained focus on cholestatic liver disease genetics (including South Asian population studies), cancer drug resistance mechanisms involving ABCB1/ABCC3, and CD36's implications in metabolic disorders. Recent work emphasizes translational applications like iPSC-derived hepatocyte models and novel transporter inhibitors. Professor Linton actively mentors postdoctoral researchers including J.J. Wharton, M. Snippe, J.K. Zolnerciks, E.J. Andress, and T.K. Ritchie, while supervising Masters, PhD, and BMedSci students. His teaching encompasses Cell Biology module coordination for first-year medical students, problem-based learning sessions, and laboratory instruction. He leads the Membrane Transport Biology research group within the Centre for Cell Biology and Cutaneous Research, maintaining collaborations with clinicians at Imperial College and King's College London to bridge basic science with clinical applications in liver disease and cancer therapeutics.

Christine HsiehView profile

Assistant Professor

• Neuroimmunology
• Innate Immunity
• Traumatic Brain Injury (TBI)
• +5 more

Christine Hsieh, PhD, BS, is an Assistant Professor in the Department of Medicine, Division of Rheumatology at the University of California, San Francisco (UCSF). She holds appointments at the San Francisco VA Medical Center and leads the Hsieh Lab, focusing on neuroimmunology and innate immunity. Her research investigates mechanisms underlying traumatic brain injury (TBI) and frontotemporal dementia (FTD), particularly the role of microglial phenotypes and macrophage activation in disease progression. The lab employs mouse models, single-cell transcriptomics, and pharmacological interventions to identify therapeutic targets for neurodegenerative conditions and TBI-related disabilities. Dr. Hsieh is affiliated with the UCSF Division of Rheumatology and the VA Immunology Group, collaborating on projects involving immunological mechanisms in neurodegenerative diseases. Education includes a BS in Molecular, Cell and Developmental Biology from UCLA (1999, Magna Cum Laude), a PhD in Immunology from Stanford University (2006), and postdoctoral training in Rheumatology at UCSF (2010). Honors include the NIH Ruth L. Kirschstein Award (2007-2009), VA Career Development Award (2011-2015), and the 2022 Innovation Award from Curia Biologics. Research interests emphasize modulation of neuroinflammation to improve disease outcomes, with a focus on translational approaches for unmet clinical needs. The lab actively recruits postdoctoral fellows and volunteers, and collaborates on neuroimmunology studies within the VA Immunology Group, which includes four principal investigators studying diverse immune-mediated conditions. Key scientific contributions include studies on TREM2 signaling in neurodegeneration, CCR2 deficiency in TBI recovery, and the role of galectin-3 in Alzheimer’s disease pathogenesis. Dr. Hsieh’s work integrates molecular immunology with clinical relevance, bridging basic science and potential therapeutic applications for brain injury and dementia.

Jasna KrizView profile

Professor

• Neuroinflammation
• Stroke
• Amyotrophic Lateral Sclerosis (ALS)
• +4 more

Dr. Jasna Kriz is a Professor at the Department of Psychiatry and Neurosciences, Faculty of Medicine, Université Laval. She serves as Deputy Director of the Integrative Neuroscience and Experimental Therapies axis at the CERVO Brain Research Centre. MD and PhD in Biomedicine & Health, University of Rijeka, Croatia Postdoctoral Training, Centre for Research in Neuroscience, McGill University (1999-2003) Her research focuses on neuroinflammation and immune cell roles in brain diseases, particularly through bioluminescent/flourescent transgenic mouse models. Key projects include: Microglial immunomodulation in ALS/FTD Withanolide-based therapeutics for neurodegeneration SRSF3 targeting in cerebral ischemia Neonatal brain injury mechanisms Galectin-3 as an endogenous immunomodulator Recent publications emphasize TDP-43 pathology, neuroinflammatory biomarkers, and translational profiling of immune responses across neurological conditions. Collaborations include the Canadian Consortium of Neurodegeneration and Aging (Team #2). Scientific recognition includes: FRSQ Senior Scholar (2011-2015) CIHR Career Award (2006-2011) FRSQ Junior Scholar (2004-2007) Current students and research staff include: Yuan Cheng Weng (Research Assistant) Hejer Boutej (Postdoc) Louis-Charles Béland (PhD student) Reza Rahimian (PhD student) Sai Sampath Thammisetty (PhD student) Senthil Krishnasamy (PhD student)

• Immunometabolism
• Innate Immunity
• MicroRNA Regulation
• +6 more

Dr. Frederick Sheedy is an Associate Professor at the School of Biochemistry & Immunology, Trinity College Dublin , Ireland. He leads research on macrophage function in health and disease , with a focus on innate immune training , microRNA regulation , and immunometabolism . His work bridges host-pathogen interactions (notably tuberculosis) and metabolic-inflammatory crosstalk in conditions like atherosclerosis and obesity. Established independent research group at TCD Key contributions to microRNA-21 and microRNA-33 roles in inflammation Collaborations with local food companies on β-glucan-induced immune training Previously held postdoctoral fellowship at NYU Dr. Sheedy’s research portfolio includes 15+ peer-reviewed publications in high-impact journals like Nature Immunology , Cell Reports , and Nature Communications . His work reveals how metabolic pathways regulate antimicrobial responses , with implications for infectious diseases , cardiovascular disorders , and nutritional immunology . Recent studies investigate β-glucan and Trained Immunity for infection resistance. Trained Immunity MicroRNA-21/33 Tuberculosis Immunology Metabolic Inflammation Fungal Immunomodulation Host-Pathogen Metabolism Scientific accolades include the Trinity Innovation Award (2020), Provost PhD Award (2020), and Researcher of the Year at Trinity Institute of Molecular Medicine (2013). His funding history spans prestigious grants from Science Foundation Ireland , Irish Research Council , Wellcome Trust , and Enterprise Ireland for studies on innate immune memory , metabolic disease , and antimicrobial immunity . Trinity Innovation Award - Industry Engagement 2020 Provost PhD Award 2020 Researcher of the Year, TCD 2013 Senior Research Fellow, TCD 2014 Dr. Sheedy’s work has been recognized through collaborations with local food industry partners and invitations to speak at international symposia. His research emphasizes translational immunology , linking nutritional interventions to immune modulation in both infectious and non-communicable diseases .

Monika SharmaView profile

Lecturer

• Neuroinflammation
• Parkinson’s Disease
• Adrenergic Receptors
• +3 more

Monika Sharma is an Instructor in the Department of Neurology at Yale School of Medicine, affiliated with the Adams Center for Parkinson's Disease Research. Her work focuses on neuroinflammation, mitochondrial dysfunction, and adrenergic receptor mechanisms in neurodegenerative disorders such as Parkinson’s disease. Her research explores the role of β2-adrenergic agonists like Salmeterol in modulating microglial activation, neuroinflammatory pathways, and mitochondrial biology. She investigates molecular mechanisms linking inflammation to neurodegeneration, with a particular emphasis on Parkinson’s disease. Publications highlight her contributions to understanding how adrenergic signaling impacts neuroinflammatory responses, therapeutic approaches for neurodegenerative diseases, and the interplay between molecular biology and clinical neuroscience. She is based in the Scherzer Lab at Yale and maintains an academic office at 101 College Street, New Haven, CT.

• Cardiovascular Science
• Platelet Physiology
• Atherosclerosis
• +5 more

Dr Ahmed Aburima is a Lecturer in Cardiovascular Science at Hull York Medical School and Principal Investigator of a British Heart Foundation (BHF)-funded research laboratory. He is also a Visiting Research Fellow at the University of Leeds and Cardiff University, and a Fellow of the Higher Education Academy since 2019. Education: BSc in Veterinary Medicine (Al-Fateh University, Libya), MSc in Biomedical Sciences (University of Bradford), PhD in Medical Sciences (Hull York Medical School) His research focuses on platelet dysfunction in cardiovascular diseases, immune suppression, and cancer progression. Key projects include rewiring the SNARE complex in platelets, platelet biomarkers for disease progression, and chronic kidney disease effects on platelet function. Recent publications highlight his work on signaling pathways (CD36, cAMP, cGMP, RhoA), oxidized lipids, thrombospondin-1, and platelet roles in thrombosis and tissue regeneration. Google Scholar articles span 2008-2025, with a 2024 outlier on US trade policy. Scientific awards include BHF Non-Clinical PhD Studentship (2019), HYMS Academic Non-Clinical Fellowship (2016), and Libyan Bureau scholarships (2006, 2002). He supervises postgraduate projects on platelet secretion machinery, cancer biomarkers, and uremic toxins in kidney disease. Collaborations include Professors Sunil Bhandari (UoH), David Allsup (HYMS), Khalid Naseem (University of Leeds), and Vladimir Buchman (Cardiff University).

• Bioorganic Chemistry
• Medicinal Chemistry
• Peptide Mimicry
• +3 more

William Lubell is a Full Professor in the Department of Chemistry within the Faculty of Arts and Science at the University of Montreal. He leads an active research laboratory focused on peptide-based drug discovery, with affiliations at the GRUM (Groupe de recherche universitaire sur le médicament) and CCVC (Centre en chimie verte et catalyse). His work bridges synthetic organic chemistry and biomedical applications, particularly in inflammation modulation and neurodegenerative disease. His research interests center on bioorganic and medicinal chemistry approaches to peptide mimicry, specializing in constrained amino acids, azapeptides, and heterocyclic scaffolds. Key areas include CD36 receptor modulation for atherosclerosis and macular degeneration, interleukin-1 receptor targeting for preterm birth prevention, and amyloid-beta oligomer detection for early Alzheimer's diagnosis. His lab develops sustainable synthesis methods while exploring peptide conformational control. Analysis of his 15 most recent publications reveals a strong trend toward therapeutic applications of modified peptides in inflammation-related pathologies (73%), neurodegenerative disease diagnostics (13%), and sustainable synthesis methodologies (14%). The work emphasizes receptor-specific modulation through conformational constraint, with significant focus on CD36 and IL-1 pathways. Dr. Lubell has secured major funding from CIHR, NSERC, and FRQNT for projects including 'Peptide-Based Discovery by Strategic Mimicry' (2025-2031), 'Interleukin-1 Receptor Modulating Therapy for Macular Degeneration' (2023-2028), and 'Biodiversity of Peptides for Human Health' (2025-2028). He has supervised over 40 graduate students since 1996, with recent PhD completions in azapeptide synthesis and inflammation modulation. His laboratory operates within the CCVC green chemistry initiative and collaborates extensively with medical researchers at the University of Montreal Health Center. Current projects include developing PET tracers for amyloid detection and peptide modulators for ischemic eye diseases, reflecting his translational research approach from bench to bedside.

Mary G. Sorci-ThomasView profile

Professor

• Lipid Metabolism
• Atherosclerosis
• Obesity
• +7 more

Mary G. Sorci-Thomas is a Professor of Medicine at the Medical College of Wisconsin (MCW), serving as Associate Director of the Cardiovascular Research Center (CVRC) and Program Director of the CVRC T32 Training Program. She holds a senior adjunct investigator position at the Versiti Blood Research Institute and has been continuously funded by NIH grants for over 33 years. Her academic journey includes tenure at Wake Forest University Medical School and leadership roles in NIH study sections. BS in Biochemistry and Chemistry from Louisiana State University PhD in Biochemistry from Wake Forest University School of Medicine Her research focuses on HDL metabolism, obesity, and cardiovascular disease, with emphasis on solving the structure-function relationships of HDL's main protein, apoA-I, and its anti-inflammatory properties. Recent work investigates the extracellular matrix protein PCPE2 in adipose tissue regulation and CD36 stabilization for cardiovascular protection. Scientific contributions include over 90 peer-reviewed articles and leadership roles in the American Heart Association (AHA), where she chaired the ATVB Council and served on the editorial boards of Arteriosclerosis, Thrombosis and Vascular Biology and Journal of Lipid Research . Her work has been recognized through AHA's Mentor of Women award and sustained NIH funding. Current lab members: Hao Xu (Lab Manager), Mirza Ahmar Beg (Postdoctoral Researcher), Marjorie Kipp (Technician) Research areas: Lipid Metabolism, Atherosclerosis, Obesity, PCPE2 protein, CD36 receptor, HDL-inflammatory signaling

Huy ONGView profile

Associate Professor

• Therapeutic Target Discovery and Validation
• Endocrinology
• Cardiovascular Pharmacology
• +7 more

Huy ONG is an Associate Professor and Emeritus Professor at the Faculty of Pharmacy, Université de Montréal. His research focuses on therapeutic target discovery, cardiovascular and metabolic pharmacology, endocrinology, and inflammation, with notable contributions to understanding CD36 receptor modulation in diseases like age-related macular degeneration and atherosclerosis. He has supervised over 30 graduate students, including PhD and Master's candidates, and leads collaborative projects on drug development for ophthalmic and cardiovascular conditions. Key affiliations include the GRUM (Drug Research Group) and RQRV (Quebec Network on Aging). His work has been supported by grants from the Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation, and Quebec's Ministry of Economy and Innovation. Notable projects include developing azapeptide ligands for treating macular degeneration and ischemic heart disease, alongside colleagues Sylvain Chemtob and William Lubell. Research highlights include groundbreaking studies on CD36's role in immunometabolism and anti-inflammatory therapies. His interdisciplinary approach bridges pharmacy, chemistry, and medicine, with potential clinical applications in near future. Over 40 years of academic service at Université de Montréal reflect his dedication to advancing pharmaceutical science.